FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma

The FDA has approved lirafugratinib as a treatment for patients with FGFR2-altered cholangiocarcinoma who have previously undergone treatment. This regulatory approval provides a new targeted therapy option for this patient group.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.